Lupus erythematosus
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
O han bi erythema purplish die-die.
Iyara labalaba ti o han ni deede loju oju.
References
Idanimọ ati iyasọtọ cutaneous lupus erythematosus (CLE) ṣe awọn italaya iwadii aisan, ṣe iyatọ rẹ lati systemic lupus erythematosus pẹlu ilowosi awọ ara. Awọn ijinlẹ aipẹ tan imọlẹ lori jiini, ayika, ati awọn ifosiwewe ajẹsara ti o wa labẹ CLE. Ifilọlẹ oogun ni pataki ti farahan bi ọkan ninu awọn okunfa pataki julọ fun CLE. Itọju pẹlu awọn itọju ti agbegbe ati eto eto, pẹlu awọn onimọ-jinlẹ ti o ni ileri (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , pẹlu ipa ti a fihan ni awọn idanwo ile-iwosan.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ni wiwa ọpọlọpọ awọn ọran awọ, diẹ ninu eyiti o le sopọ si awọn iṣoro ilera ti o gbooro. O ti pin si awọn oriṣi oriṣiriṣi, gẹgẹbi acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE ni ninu discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus jẹ ẹgbẹ kan ti awọn arun autoimmune ti o le ni ipa lori awọn ẹya oriṣiriṣi ara. Diẹ ninu awọn oriṣi, bii systemic lupus erythematosus (SLE) , ni ipa lori ọpọlọpọ awọn ara, lakoko ti awọn miiran, bii cutaneous lupus erythematosus (CLE) , ni pataki lori awọ ara. A ṣe iyatọ awọn oriṣi CLE ti o da lori akojọpọ awọn ami ile-iwosan, idanwo ara, ati awọn idanwo ẹjẹ, ṣugbọn iyatọ pupọ wa laarin awọn eniyan kọọkan. Awọn iṣoro awọ-ara nigbagbogbo dagbasoke nitori awọn okunfa bii ifihan si imọlẹ oorun, siga, tabi awọn oogun kan.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Idi ti lupus erythematosus ko han gbangba. Lara awọn ibeji kanna, ti ọkan ba kan ni anfani 24% ti ekeji yoo tun wa. Awọn homonu ibalopo ti obinrin, imọlẹ oorun, mimu siga, aipe Vitamin D, ati awọn akoran kan tun gbagbọ lati mu eewu naa pọ si.
Awọn itọju le pẹlu NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, ati methotrexate. Botilẹjẹpe awọn corticosteroids munadoko, awọn abajade lilo igba pipẹ ni awọn ipa ẹgbẹ.